Your session is about to expire
← Back to Search
89Zr-ss-pertuzumab Imaging for Breast Cancer
Study Summary
This trial is testing whether a new cancer drug is safe for people with HER2+ cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Your liver enzymes (AST/ALT) are more than double the normal limit.I am 18 years old or older.My cancer is HER2 positive based on specific guidelines or tests.Your kidney function, measured by a blood test called creatinine, is more than double the normal level.You are not expected to live for more than 3 months.My cancer has low HER2 levels, confirmed by specific tests.My cancer is confirmed to be HER2-positive or HER2-low.I weigh over 450 pounds and cannot have a PET/CT scan.I have a cancerous lesion that's been imaged within the last 2 months.I can take care of myself and perform daily activities.
- Group 1: HER2-positive malignancy
- Group 2: HER2-low malignancy
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
To what extent is the population involved in this research endeavor?
"Affirmative, according to clinicaltrials.gov the trial is actively recruiting participants who were initially posted on November 30th 2020 and last edited September 13th 2022. At this time, 20 individuals are being recruited from two distinct sites."
Has the FDA given authorization for 89Zr-ss-pertuzumab PET/CT imaging?
"Taking into account the limited amount of safety and efficacy data, our team at Power have assigned 89Zr-ss-pertuzumab PET/CT a score of 1 on their scale from 1 to 3."
Has recruitment for this medical trial commenced?
"According to the records found on clinicaltrials.gov, enrollment for this medical research is ongoing. It was initially posted in November of 2020 and its details were most recently edited in September 2022."
Is this a pioneering endeavor in its field?
"According to current information, there are 90 active studies involving 89Zr-ss-pertuzumab PET/CT across 1397 cities and 62 countries. This medical technology was first tested in 2008 when Hoffmann La Roche sponsored a Phase 2 trial that included 720 patients. Over the last 12 years, 69 different trials utilizing this method have been concluded."
What previous experiments have included 89Zr-ss-pertuzumab PET/CT as one of their tools?
"The first study of 89Zr-ss-pertuzumab PET/CT occured in 2008 at SCRI Tennessee Oncology Chattanooga. Over the last 12 years, 69 trials have been concluded with 90 still underway; particularly, many are located around Newport Beach, California."
To what maladies is 89Zr-ss-pertuzumab PET/CT commonly prescribed?
"89Zr-ss-pertuzumab PET/CT is usually employed to treat the therapeutic procedure in question, but can also provide relief from brca1 gene, inflammatory breast cancer (ibc), and malignant neoplasms."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger